Publications

  • Ortiz de Landaluce L. Gabapentin and pregabalin and risk of atrial fibrillation in the elderly: a population-based cohort study in an electronic presciption database. Drug Safety 2018;:1-7.  Link
  • Faillie JL. A new risk of bias checklist applicable to randomized trials, observational studies and systematic reviews was developed and validated to be used for systematic reviews focusing on drug adverse events. J Clin Epidemiol 2017;:1.  Link
  • Giner M. Effectiveness and safety of drugs used for stroke prevention in a cohort of non-valvular atrial fibrillation patients from a primary care electronic database. Drug Safety 2017;26:97-107.
  • Nicoletti P. Association of liver injury from specific drugs, or grups of drugs, with polymorphisms in HLA and other genes in a genome-wide association study. Gastroenterology 2017;152:1078-1089.
  • Ferrer P. Systematic review and meta-analysis: macrolides- and amoxicillin/clavulanate-induced acute liver injury. Basic & Clin Pharmacol Toxicol 2016;119:3-9.
  • Laporte JR. Fifty years of pharmacovigilance - Medicines safety and public health. Pharmacoepidemiol Drug Safety 2016;25:725-732.
  • Klungel OH. Multi-centre, multi-database studies with common protocols: lessons learnt from the IMI PROTECT project. Pharmacoepidemiol Drug Safety 2016;25:156-165.  Link
  • Corrêa de Matos G. The inconveniences of polysemy in the database era - don't call it "drug" unless you mean it. Pharmacoepidemiology and Drug Safety 2015;24:673-675.  Link
  • Iavecchia L. Insuficiencia renal aguda relacionada con medicamentos en pacientes hospitalizados. Nefrologia 2015;35:523-532.
  • Troncoso A. Dabigatran and rivaroxaban prescription for atrial fibrillation in Catalonia, Spain: the need to manage the introduction of new drugs. Eur J Clin Pharmacol 2014;70:249-250.
  • Godman B. Dabigatran - a continuing exemplar case history demostrating the need for comprehensive models to optimize the utilization of new drugs. Frontiers in Pharmacology 2014;5:1-11.  Link
  • Ferrer P. Cross-national comparison of antiepileptic drug use: Catalonia, Denmark and Norway. Epidemiology Biostatistics and Public Health 2014;11:e9495-09.  Link
  • Urban TJ. Limited contribution of common genetic variants to risk for liver injury due to a variety of drugs. Pharmacogenetics and Genomics 2012;22:784-795.
  • Agustí A. Exposure to medicines among patients admitted for hip fracture and the case-fatality rate at 1 year: a longitudinal study. Eur J Clin Pharmacol 2012;68:1525-1531.  Link
  • Théophile H. The case-population study design: an analysis of its application in pharmacovigilance. Drug Safety 2011;34:861-868.  Link
  • Ubeira FM. Synergism between prior anisakis simplex infections and intake of NSAIDs, on the risk of upper digestive bleeding: a case-control study. PLOS Neglected Tropical Diseases 2011;5:0.  Link
  • Sabaté M. Paracetamol in therapeutic dosages and acute liver injury: causality assessment in a prospective case series. BMC Gastroenterology 2011;11:0.  Link
  • Carvajal A. Selective serotonin reuptake inhibitors and gastrointestinal bleeding: a case-control study. PLOS ONE 2011;6:0.  Link
  • Laporte JR. Connaissance des effets indésirables des médicaments: pour une pharmacovigilance plus ambitieuse. Conférence-débat. Pilule d'Or Prescrire 2010;:1-5.  Link
  • Sánchez-Diz P. Prevalence of CYPT2C9 polymorphisms in the south of Europe. Pharmacogenomics J 2009;9:306-310.
  • Ibáñez L. Proton pump inhibitors and risk of upper gastrointestinal bleeding in NSAID users. Am J Gastroenterol 2008;103:2658-2659.
  • Vidal X. Risk of upper gastrointestinal bleeding and the degree of serotonin reuptake inhibition by antidepressants. A case-control study. Drug Safety 2008;31:159-168.  Link
  • Ibáñez L. Agranulocytosis induced by nonchemotherapy drugs. Ann Intern Med 2008;148:319-320.
  • Ibáñez L. Use of granulocyte colony-stimulating fractor (G-CSF) and outcome in patients with non-chemotherapy agranulocytosis. Pharmacoepidemiol Drug Safety 2008;17:224-228.  Link
  • Montané E. Epidemiology of aplastic anemia: a prospective multicenter study. Haematologica 2008;93:518-523.  Link
  • Waller P. European commission consultation on pharmacovigilance. Pharmacoepidemiol Drug Safety 2008;17:108-109.
  • Sabaté M. Toxicity of chronic paracetamol ingestion: author's reply. Aliment Pharmacol Ther 2007;26:1543-1546.  Link
  • Sabaté M. Risk of acute liver injury associated with the use of drugs: a multicentre population survey. Aliment Pharmacol Ther 2007;25:1401-1409.  Link
  • Pedrós C. Reaccions adverses a medicaments. Butll Farmacoterap Hosp Santa Maria de Lleida 2006;21:1-3.
  • Kaufman DW. Relative incidence of agranulocytosis and aplastic anemia. Am J Hematol 2006;81:65-67.  Link
  • Ibáñez L. Upper gastrointestinal bleeding associated with antiplatelet drugs. Aliment Pharmacol Ther 2006;23:235-242.  Link
  • Sabaté M. Acute liver disease and risk associated to drugs: a case-population aproach. Basic & Clin Pharmacol Toxicol 2005;97:111.
  • Ibáñez L. Case-control study of regular analgesic and nonsteroidal anti-inflammatory use and end-stage renal disease. Kidney Int 2005;67:2393-2398.  Link
  • Xiol X. Hepatotoxicitat aguda greu: resultats d'un estudi cas-població. Ann Med (Barc) 2005;88:40.
  • Sabaté M. Hepatotoxicidad aguda grave: resultados de un estudio caso-población. XXX Congreso Nacional de la Asociación Española para el Estudio del Hígado. Gastroenterol Hepatol 2005;38:53.
  • Ibáñez I. Agranulocytosis associated with dipyrone (metamizol). Eur J Clin Pharmacol 2005;60:821-829.  Link
  • Ibáñez L. Population-based drug-induced agranulocytosis. Arch Intern Med 2005;165:869-874.  Link
  • Ibáñez L. Effect of gastroprotective agents on the risk of upper gastrointestinal bleeding asociated with low-dose acetylsalicylic acid use. Basic & Clin Pharmacol Toxicol 2005;97:110.
  • Laporte JR. Upper gastrointestinal bleeding associated with the use of NSAIDs. Newer versus older agents. Drug Safety 2004;27:411-420.  Link
  • Ibáñez L. Upper grastrointestinal bleeding and antiplatelet drugs. Pharmacoepidemiol Drug Safety 2004;13:142-143.
  • Théophile H. Incidence of agranulocytosis in Southwest France. Eur J Epidemiol 2004;19:563-565.  Link
  • Sabaté M. Atribución de causalidad a fármacos en pacientes con patología hepática aguda grave: concordancia entre clínicos. Gastroenterol Hepatol 2004;27:112.
  • Vallano A. Use of venous thromboprophylaxis and adherence to guideline recommendations: a cross-sectional study. Thrombosis Journal 2004;2:3.  Link
  • Pérez Peña J. Una politica di farmaci basata sulle necessità e sulle richieste: la ricerca nella rete cubana di farmacoepidemiologia. Ricerca & Practica 2003;19:96-102.
  • Diogène E. The Cuban experience in focusing pharmaceuticals policy to health population needs: initial results of the National Pharmacoepidemiology Network (1996-2001). Pharmacoepidemiol Drug Safety 2003;12:405-407.  Link
  • The International Collaborative Study of Severe Anaphylaxis. Risk of anaphylaxis in a hospital population in relation to the use of various drugs: an international study. Pharmacoepidemiol Drug Safety 2003;12:195-202.
  • Figueras A. Failures of the therapeutic chain as a cause of drug ineffectiveness. Br Med J 2003;326:895-896.  Link
  • Ibáñez L. Prospective surveillance of acute serious liver disease unrelated to infectious, obstructive, or metabolic disease: epidemiological and clinical features, and exposure to drugs. J Hepatol 2002;37:592-600.  Link
  • Grupo para el estudio de la agranulocitosis y la aplasia medular de Barcelona (GEAAMB). Utilización de factores de crecimiento de granulocitos en 145 episdios de agranulocitosis. Haematologica 2002;87:128.
  • Capellà D. Case-population studies in pharmacoepidemiology. Drug Safety 2002;25:7-19.  Link
  • Lewis SC. Dose-response relationships between individual nonaspirin nonsteroidal anti-inflammatory drugs (NANSAIDs) and serious upper gastrointestinal bleeding: a meta-analysis based on invididual patient data. Br J Clin Pharmacol 2002;54:320-326.  Link
  • Ibáñez L. Acute serious liver disease of uncertain etiology. Epidemiological and clinical features of dead and transplanted patients. Meth Find Exp Clin Pharmacol 2001;23:340.
  • Ibáñez L. Agranulocytosis associated with calcium dobesilate. Clinical course and risk estimation with the case-control and the case-population approaches. Eur J Clin Pharmacol 2000;56:763-767.  Link
  • Cobos N. Dnase use in the daily care of cystic fibrosis. Who benefits from it and to what extent? Results of a cohort study of 199 patients in 13 centres. Eur J Pediatr 2000;159:176-181.  Link
  • Ibáñez L. Epidemiology and risk factors of aplastic anaemia. In: Velo G, Perucca E (eds), VII World Conference on Clinical Pharmacology and Therapeutics & 4th Congress of the European Association for Clinical Pharmacology and Therapeutics (EACPT), abstract nº 11. Br J Clin Pharmac 2000;49:4.
  • Diogène E. Cuba: a national drug policy oriented to health population needs. In: Velo G, Perucca E (eds), VII World Conference on Clinical Pharmacology and Therapeutics & 4th Congress of the European Association for Clinical Pharmacology and Therapeutics (EACPT), abstract nº 20. Br J Clin Pharmac 2000;49:6.
  • Ibáñez L. Drug-induced acute liver injury (ALI). In: Velo G, Perucca E (eds), VII World Conference on Clinical Pharmacology and Therapeutics & 4th Congress of the European Association for Clinical Pharmacology and Therapeutics (EACPT), abstract nº 308. Br J Clin Pharmac 2000;49:81-82.
  • Ibáñez L. Agranulocytosis induced by pyrithyldione, a sedative hypnotic drug. Eur J Clin Pharmacol 2000;55:761-764.  Link
  • Orriols R. Inhaled antibiotic therapy in non-cystic fibrosis patients with bronchiectasis and chronic bronchial infection by Pseudomonas aeruginosa. Respiratory Medicine 1999;93:476-480.  Link
  • Grupo de Estudio Multicéntrico de Hepatotoxicidad Aguda (GEMHA). Hepatotoxicidad asociada al uso de medicamentos. In: VIII Congreso de la Sociedad Catalana de Digestología. Gastroenterología y Hepatología 1999;22:43.
  • Laporte JR. Efectos adversos de los medicamentos: la parte del témpano que se oculta. Med Clín (Barc) 1999;112:516-517.
  • Laporte JR. Possible association between ocular chloramphenicol and aplastic anaemia - the absolute risk is very low. Br J Clin Pharmacol 1998;46:181-184.  Link
  • Laporte JR. Fatal aplastic anaemia associated with nifedipine. Lancet 1998;352:619-620.  Link
  • Kaufman D. Risk of anaphylaxis among hospital patients exposed to various drugs. Pharmacoepidemiology and Drug Safety 1998;7:S114-S115.
  • Martínez MJ. Case-control study of regular analgesic use and end-stage renal disease. Meth Find Exp Clin Pharmacol 1998;20:116.
  • Capellà D. European network for the case-population surveillance of rare diseases (Euronet). A prospective feasibility study. Eur J Clin Pharmacol 1998;53:299-302.  Link
  • The International Collaborative Study of Severe Anaphylaxis. An epidemiological study of severe anaphylactic and anaphylactoid reactions among hospital patients: methods and overall risks. Epidemiology 1998;9:141-146.  Link
  • Laporte JR. Efectos adversos de los medicamentos: la parte oculta del témpano. Med Clín (Barc) 1998;111:101-102.
  • Kelly JP. Contrast media-associated incidence of anaphylaxis. Pharmacoepidemiology and Drug Safety 1997;6:S104.
  • Cucurull E. Dislipemia en pacientes sometidos a trasplante hepático. Gastroenterol Hepatol 1995;18:210.
  • Santiveri C. Eficacia del tratamiento antibiótico inhalado ambulatorio en pacientes no mucoviscidóticos con bronquiectasias colonizadas por Pseudomonas aeruginosa. Arch Bronconeumol 1995;31:42.
  • Laporte JR. Gastrointestinal bleeding is common. Br Med J 1995;311:391-392.
  • Kaufman DW. A study of severe anaphylaxis among hospital patients: methods and incidence. Pharmacoepidemiology Drug Safety 1995;4:S88.
  • Bégaud B. Upper gastrointestinal bleeding associated with analgesics and NSAID use: a case-control study. J Rheumatol 1993;20:1443-1444.
  • Laporte JR. Relating series of cases with medicines consumption by the general population. Introductory remarks. Rev Farmacol Clín Exp 1991;8:11-12.
  • Ibáñez L. Agranulocytosis associated with aprindine and other antiarrhythmic drugs: an epidemiological approach. Eur Heart J 1991;12:639-641.
  • Figueras A. Misuse of aspirin for abdominal discomfort. Lancet 1991;338:506-507.
  • Laporte JR. Upper gastrointestinal bleeding in relation to previous use of analgesics and non-steroidal anti-inflammatory drugs. Lancet 1991;337:85-89.
  • Morlans M. End-stage renal disease and non-narcotic analgesics: a case-control study. Br J Clin Pharmac 1990;30:717-723.
  • Ibáñez L. Reacciones adversas a medicamentos que motivan atención en el Servicio de Urgencias del Hospital General Vall d'Hebron. Rev Farmacol Clín Exp 1990;7:99.
  • Ibáñez L. Agranulocitosis asociada al uso de antitiroideos. Rev Farmacol Clín Exp 1990;7:100.
  • Laporte JR. Agranulocytosis induced by cinepazide. Eur J Clin Pharmacol 1990;38:387-388.
  • Capellà D. Fenotipo hidroxilador de la debrisoquina y síndrome de Parkinson. Rev Farmacol Clín Exp 1990;6:273.
  • Juan J. Pathophysiology and clinical course of agranulocytosis associated with parenteral high doses of ß-lactam antibiotics. Eur J Clin Pharmacol 1989;36:174.
  • International Agranulocytosis and Aplastic Anemia Study. Anti-infective drug use in relation to the risk of agranulocytosis and aplastic anemia. Arch Intern Med 1989;149:1036-1040.  Link
  • Moreno V. Comparación de modelos para valorar la dosis hemorrágica de antiinflamatorios. Rev Farmacol Clín Exp 1988;5:250.
  • International Agranulocytosis and Aplastic Anaemia Study. Risk of agranulocytosis and aplastic anaemia in relation to use of antithyroid drugs. Br Med J 1988;297:262-265.  Link
  • Participants of the IAAAS. Reply to Kramer, Lane and Hutchinson. The International Agranulocytosis and Aplastic Anemia Study. J Chron Dis 1987;40:1083-1085.
  • International Agranulocytosis and Aplastic Anemia Study. Incidence of aplastic anemia: the relevance of diagnostic criteria. Blood 1987;70:1718-1721.  Link
  • Laporte JR. Blood dyscrasias and the relative safety of non-narcotic analgesics. Lancet 1987;329:809.
  • Laporte JR. Agranulocitosis y anemia aplásica inducidas por fármacos. Med Clín (Barc) 1987;88:555-558.
  • Laporte JR. El desarrollo de los métodos de farmacovigilancia. Medicine 1987;93:545-552.
  • The International Agranulocytosis and Aplastic Anemia Study. Risks of agranulocytosis and aplastic anemia. A first report of their relation to drug use with special reference to analgesics. JAMA 1986;256:1749-1757.  Link
  • Laporte JR. Detección y cuantificación de reacciones adversas sobre el embrión y el feto: estudios y registros de malformaciones congénitas. Med Clín (Barc) 1986;86:31-35.
  • Laporte JR. Detección y cuantificación de reacciones adversas sobre el embrión y el feto. Med Clín (Barc) 1986;87:171.
  • Laporte JR. Farmacología clínica y epidemiología: dos desarrollos convergentes. Rev Farmacol Clín Exp 1985;2:95-98.
  • Arboix M. The potentiation of acenocoumarol anticoagulant effect by amiodarone. Br J Clin Pharmac 1984;18:355-360.
  • International Agranulocytosis and Aplastic Anemia Study. The design of a study of the drug etiology of agranulocytosis and aplastic anemia. Eur J Clin Pharmacol 1983;24:833-836.
  • Arboix M. Monitorización del tratamiento con anticoagulantes en pacientes portadores de prótesis valvulares cardiacas. Arch Farmacol Toxicol 1983;9:79-82.
  • Ibáñez L. Agranulocitosis en el área de Barcelona. Resultados de dos años de seguimiento. Arch Farmacol Toxicol 1983;9:103-108.
  • Carné X. Aplasia medular en el área de Barcelona. Resultados de dos años de seguimiento. Arch Farmacol Toxicol 1983;9:115-120.
  • Frati ME. Acute severe poisoning in Spain: clinical outcome related to the implicated drugs. Human Toxicol 1983;2:625-632.
  • Laporte JR. La evaluación de los medicamentos tras su comercialización. Med Clín (Barc) 1983;81:772-774.
  • Arboix M. Monitorización del tratamiento con anticoagulantes en pacientes portadores de prótesis valvulares cardíacas. Biol Clin Hematol 1982;4:165-168.
  • Camí J. Acute poisoning in Barcelona, Spain. Clin Toxicol 1980;17:421-428.  Link